Tagrisso Reimbursed In Korea, After Difficult Price Negotiations

 
• By Jung Won Shin

Korea's National Health Insurance Service and AstraZeneca reach an agreement on reimbursement of Tagrisso, sharply reducing financial burdens of NSCLC patients in the country. Tough price negotiations between the two sides underlines the difficulties pricey innovative drugs face to get reimbursed in the country.

lung illustration

More from Market Access

More from Pink Sheet